Analysis

Today’s guest post comes from Jenna Mitby-Manning, Senior Director of Commercial Strategy & Insights, Access & Adherence at RxCrossroads by McKesson.

Jenna explains how data-driven solutions accelerate time to therapy, improve patient outcomes, and allow biopharma companies to make informed strategic decisions.

Click here to learn more about RxCrossroads' therapy access and adherence solutions.

Read on for Jenna’s insights.

Posted by Drug Channels Institute, an HMP Global company on Friday, October 2, 2020

Labels: Guest Post, Sponsored Post

Autumn is here! We’ve been squirrelling away these acorns from the mighty Drug Channels oaks:

• I agree. FQHCs are not the problem in 340B.

• Brand-name drug prices keep on dropping

• It’s official: CVS Health’s Zinc GPO actually exists!

• Telehealth takes a dive

Plus, vote for your 10 favorite songs of all time!

P.S. This month, @DrugChannels exceeded 10,000 followers on Twitter. Thank you to everyone who follows my curated links to neat stuff! Click here to join the crowd.

You can also join my 12.3K followers on LinkedIn.

Posted by Drug Channels Institute, an HMP Global company on Wednesday, September 30, 2020

Labels: COVID-19, Gross-to-Net Bubble, Group Purchasing Organizations (GPOs), 340B, PBMs

Informa Connect-CBI’s 8th Annual Coupon and Copay Forum

October 13-16, 2020 | Virtual Event

www.informaconnect.com/coupon-copay/

Exclusive Offer for Drug Channels Readers – View the complete agenda and register today – Be sure to use your exclusive promo code USAVE3 to save $300*

It’s time to talk. As managing copay programs continues to be significantly more complex, it is imperative to stay on top of current trends, emerging regulations and future legislation. Hundreds of leaders in patient access and affordability have benefited from Informa Connect- CBI’s Coupon and Copay Forum conference series. Join key stakeholders at this timely meeting and examine the design of coupon and copay programs aimed at driving the most effective and efficient patient access and affordability.

Unlike a webinar or zoom training, Coupon and Copay serves as a full virtual 4-day conference experience. As always, the caliber of content and peer-to-peer engagement is second to none. Experts from Diverse Biotech, Mallinckrodt Pharmaceuticals, ConnectiveRX, Orange Grove Bio, National Hemophilia Foundation, Akebia Therapeutics, Vanderbilt University Medical Center, HHS, AbbVie, PhRMA, The AIDs Institute, National Alliance of Healthcare Purchaser Coalitions, Sol-Gel Technologies, The GW School of Medicine, Apellis Pharmaceuticals, Innocoll Pharmaceuticals, Tris Pharma, kaléo and more will lead robust discussions on compelling topics, including:

• Innovative copay program design and operations
• Impact of COVID-19 on affordability
• Formulary barriers, increasing patient awareness and driving adherence
• Performance metrics to justify the cost of copay programs
• Pharmacy surveillance of specialty brand copay programs
• Breaking down current barriers to prescription drug access and assistance
• PAP compliance trends and implications of copay programs
• Copay accumulator and maximizer programs
• Employer shifts in benefit plan design to address the growing costs of advanced therapeutics

Unparalleled Virtual Capabilities:

• Interactive presentations and panels
• Live Q&A and polling
• Live and on-demand sessions, all available 30-days post-event to review at your leisure
• 1-1 meeting opportunities and peer-to-peer engagement
• Sophisticated and seamless scheduling tools

Exclusive Offer for Drug Channels Readers – View the complete agenda and register today – Be sure to use your exclusive promo code USAVE3 to save $300*

Informa Connect-CBI will see you there!

*Discount offer valid through 10/9/2020; applies to standard rates only and may not be combined with other offers, categories, promotions or applied to an existing registration. Offer not valid on workshop-only or non-profit registrations.

---

The content of Sponsored Posts does not necessarily reflect the views of Pembroke Consulting, Inc., Drug Channels, or any of its employees.

Posted by Drug Channels Institute, an HMP Global company on Tuesday, September 29, 2020

Labels: Sponsored Post

Today’s guest post comes from Julia Laurin, Chief Product Officer at ConnectiveRx.

Julia discusses the medication access and adherence challenges specialty patients face. She introduces us to mobileCare Manager™ a mobile platform built specifically for the specialty patient experience.

To learn more about ConnectiveRx’s mobile engagement platform, download their one-pager or visit their website to connect with one of their experts.

Read on for Julia’s insights.

Posted by Drug Channels Institute, an HMP Global company on Friday, September 25, 2020

Labels: Guest Post, Sponsored Post

Will COVID-19 trigger long-term share gains for specialty pharmacies as suppliers to hospitals and physician offices?

Before the pandemic, specialty pharmacies—via white, brown, and clear bagging—had already displaced buy-and-bill distribution channels for a substantial chunk of provider-administered specialty drugs. See below for detailed data on oncology and non-oncology products.

We estimate that in the first half of 2020, the coronavirus pandemic accelerated this shift. Some of the changes will likely be transitory, as patients return to their healthcare providers. But payers will try to retain some of these gains—especially if they also own a specialty pharmacy.

Read on and see if you agree.

Posted by Drug Channels Institute, an HMP Global company on Wednesday, September 23, 2020

Labels: Hospitals, Physicians, Pharmacy, Specialty Drugs, Buy-and-Bill, Channel Management, PBMs

On October 13, 2020, Drug Channels Institute will release The 2020–21 Economic Report on Pharmaceutical Wholesalers and Specialty Distributors. This report—our eleventh edition—remains the most comprehensive, fact-based tool for understanding and analyzing the large and growing U.S. pharmaceutical distribution industry. Notable new material in the 2020-21 edition includes three sections that address COVID-19 and its impact on wholesalers.

We are providing you with the opportunity to preorder this thoroughly updated and revised 2020-21 edition at special discounted prices. This means that you can be among the first to access our new report. Those who preorder will receive a download link before October 13.

CLICK HERE to download a free pre-publication draft overview
(including the Table of Contents and a List of Exhibits).

You can pay online with all major credit cards (Visa, MasterCard, American Express, and Discover) or via PayPal. Click here to email us if you would like to pay by corporate purchase order or check.

Preorder and launch pricing discounts will be valid through October 23, 2020.

Posted by Drug Channels Institute, an HMP Global company on Tuesday, September 22, 2020

Labels: Blog Administration, Industry Trends, Wholesalers

15th Hub, SPP and eServices Summit

September 29-October 2, 2020 | Virtual Event

www.informaconnect.com/hub-spp-eservices/

This important event convenes key stakeholders including manufacturers, specialty pharmacies, hubs, payers, PBMs, physicians and more to explore strategies for developing and integrating hub programs and other patient-centric services to ensure product access and optimal reimbursement.

Drug Channels readers will save $300 off the standard registration rate when they use code MDU494.*

In-Depth Discussions and Actionable Takeaways on Critical Topics: Hub Excellence

• Innovative Affordability Strategies and Hub Models for Specialty Products
• Examine Support Service Model Design and Strategies for Implementation
• Training and Staff Advancement for Hub Excellence through Resource Management
• Strategic Integration of Patient Support, Distribution, Field and Commercial Strategies for Innovative Therapies

SPP Partnering

• Ask the Experts—Elevate Stakeholder Collaboration to Optimize Patient Access
• Uncover Innovative Strategies to Optimize SP Networks
• Striking the Right Balance—A Look at the Level of Integration Between Hub and Pharmacy
• Pharmacy Perspective—Assess the Impact of Real-Time Benefit Verification on Patient Access

eRx, ePrior Auth and eServices

• ONC Keynote Address—Reducing Regulatory and Administrative Burden Relating to the Use of Health IT and EHRs
• Manufacturer Insights—Assess Opportunities to Prevent Un-Due Delay of Patient Care
• Standards Update—Navigate NCPDP Initiatives, Guidance and Future Proposals for Innovation
• Navigate ePrior Authorization and Real-Time Benefit Verification Complexities within Medicare

Featured Speakers:

• Alicia Dixon, MHA, Director, Patient Access and Reimbursement, Tricidia, Inc.
• John Wiedemann, Director of Patient Support Service, Retrophin
• Jackie Barnard, Associate Director, Field Reimbursement, Paratek Pharmaceuticals
• Bill Goodson, Director, Patient Access and Reimbursement Services, Eisai US
• Keith White, Vice President and Head, Global Market Access, Corbus Pharmaceuticals
• Stephen Samuel, Chief Executive Officer, Premier Specialty Pharmacy Services
• John Klimek, R.Ph., Senior Vice President, Standards & IT, NCPDP
• Sarah Krug, Executive Director, Cancer 101
• Sheila M. Arquette, R.Ph., Executive Director, National Association of Specialty Pharmacy (NASP)
• David Kowalsky, Director, Market Access and Patient Services, EyePoint Pharmaceuticals
• Andrew Gettinger, Chief Clinical Officer, ONC at US Department of Health & Human Services
• And more!

REGISTER TODAY

Drug Channels readers will save $300 off the standard registration rate when they use code MDU494.*

*Offer applies to standard rates only and may not be combined with other offers, category rates, promotions or applied to an existing registration. Offer not valid on workshop only or academic/non-profit registrations.

---

The content of Sponsored Posts does not necessarily reflect the views of Pembroke Consulting, Inc., Drug Channels, or any of its employees.

Posted by Drug Channels Institute, an HMP Global company on Monday, September 21, 2020

Labels: Sponsored Post

Today’s guest post comes from Ela Lourido, Vice President of Business Development at Biologics by Mckesson.

Ela discusses the important role independent specialty pharmacies play in educating payers, supporting patients, and ultimately getting potentially life-saving therapies into the hands of patients.

Click here to learn more about Biologics by McKesson's patient access services for biopharmaceutical manufacturing companies.

Read on for Ela’s insights.

Posted by Drug Channels Institute, an HMP Global company on Friday, September 18, 2020

Labels: Guest Post, Sponsored Post

Last Friday, The Wall Street Journal published my opinion piece: The Federal Program That Keeps Insulin Prices High. The article text is pasted below for those who don't subscribe.

I summarize issues with the role of contract pharmacies in the 340B Drug Pricing Program. My arguments will be familiar to regular readers of Drug Channels. I wrote this piece for a general business audience, so it's highly readable and omits industry insider terminology. To help you get the most from the article, I have included additional links to source materials in the text.

Note that my commentary focuses primarily on hospitals, which account for the vast majority of 340B program sales. Federal grantees are more likely to pass discounted 340B prices to needy patients. However, grantees should consider my warning from 2014: The good apples—the 340B entities that require additional financial support to support needy patients—should be worried that the bad ones could rot away the program for everyone.

Please share your comments below and I'll respond where appropriate.

Posted by Drug Channels Institute, an HMP Global company on Tuesday, September 15, 2020

Labels: Hospitals, 340B, Health Care Policy, Pharmacy, PBMs

We are proud to bring you something new for 2021!

Join Dr. Adam J. Fein, CEO of Drug Channels Institute (DCI), for five live video webinars—one every calendar quarter, starting in the fourth quarter of 2020. These live, interactive events will be broadcast via Zoom from the Drug Channels Video studio in beautiful downtown Philadelphia.

During these quarterly updates, Dr. Fein will address the latest issues confronting the U.S. drug channel. Topics will be determined based on what’s happening—trends, policy changes, executive orders, company announcements, and more. He’ll also share DCI’s latest market data to help you stay on top of new developments. You will be able to use these events as both a capstone of your quarterly learning and a touchpoint for the future.

The 75-minute events are scheduled for 12:00 p.m. to 1:15 p.m. ET on:

• December 18, 2020 (Drug Channels Outlook: What You Need to Watch in 2021)

• March 26, 2021 (Drug Channels Update: 2021Q1)

• June 25, 2021 (Drug Channels Update: 2021Q2)

• September 24, 2021 (Drug Channels Update: 2021Q3)

• December 17, 2021 (Drug Channels Outlook: What You Need to Watch in 2022)

PLUS: Dr. Fein will take your questions during each event. We will also offer an opportunity to submit questions in advance of each event.

Read on for full details on pricing, including substantial discounts for multiple sites.

Posted by Drug Channels Institute, an HMP Global company on Monday, September 14, 2020

Labels: Blog Administration